The European Medicines Agency (EMA) has granted orphan drug designation to Purespring Therapeutics’ PS-002 in IgA nephropathy (IgAN), an autoimmune kidney disease that primarily affects young adults. Orphan drug designation in the European Union (EU) provides incentives including market exclusivity, protocol assistance (guidance on study design and scientific evaluation) and regulatory fee reductions. In patients […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!